Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Ureteral Calculi: early-phase trial registry

1 of 5 indexed Ureteral Calculi trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Ureteral Calculi: 5 US clinical trials tracked, 1 recruiting.

Ureteral Calculi is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Watson Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition ureteral-calculi

OPEN 1 | RECR 20% | LATE 0 | EARLY 1 | RANK #3391 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Ureteral Calculi (this)20%
Open-enrollment share among volume-matched conditions near Ureteral Calculi

Ureteral Calculi lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Ureteral Calculi on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Ureteral Calculi is recruiting below its size-band peers.

    1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Ureteral Calculi research.

    Watson Pharmaceuticals accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Ureteral Calculi trials plan to enrol fewer than 100 people.

    Median target enrolment is 74 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.

  4. Ureteral Calculi research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Ureteral Calculi records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

renal and bladder ultrasound with ureteral jet assessment Device
1 trials
PCNL Procedure
1 trials
silodosin Drug
1 trials
Burst Wave Lithotripsy Device
1 trials
Oxybutynin Drug
1 trials
Methocarbamol Drug
1 trials
placebo Drug
1 trials

US sites by state

Facility locations filed on Ureteral Calculi trials. A trial with sites in several states counts in each.

Ohio 2 trials
Missouri 2 trials
Washington 1 trials
New York 1 trials
New Jersey 1 trials
Kansas 1 trials
Indiana 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Ureteral Calculi page

5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ureteral Calculi condition card totals 5 registered trials; most-linked intervention renal and bladder ultrasound with ureteral jet assessment; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.